Previous close | 73.14 |
Open | 73.14 |
Bid | 66.20 |
Ask | 68.45 |
Strike | 85.00 |
Expiry date | 2024-07-19 |
Day's range | 73.13 - 73.14 |
Contract range | N/A |
Volume | |
Open interest | 59 |
Novavax stock is soaring on news the FDA set a deadline by which to approve or reject its COVID-19 vaccine.
Moderna stock is on the rise amid a bevy of news, including FDA approval for its RSV vaccine. Is MRNA stock a buy right now?
Drugmakers are aiming to launch this year’s shots by the beginning of September but have been waiting on the FDA to decide which strain of the virus to target. At their meeting on Wednesday, the FDA’s advisers nevertheless recommended that this year’s shots target JN.1, saying they expect a JN.1 shot to offer sufficient protection against the strain’s descendants.